Results 211 to 220 of about 2,050,687 (327)

Tables for Testing Significance In a 2 × 3 Contingency Table

open access: yes, 1963
M. Natrella   +4 more
semanticscholar   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Developing medication independence: The experience of UK teenagers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims There is a progression through childhood from being provided medications by caregivers to having to take responsibility for medications yourself, but little is known about when the transition of adolescents managing medicines begins. The aim of this study was to obtain a cross‐sectional sample of UK adolescents and when they become independent ...
Holly Hutchins   +5 more
wiley   +1 more source

Pharmacists expand access to contingency management in patients with substance use disorders. [PDF]

open access: yesMent Health Clin
Salsman M   +5 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse   +3 more
wiley   +1 more source

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp   +6 more
wiley   +1 more source

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy